NCT03735264View on ClinicalTrials.gov

Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）

PHASE2UnknownINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

October 14, 2020

Study Completion Date

October 15, 2020

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Anlotinib Hydrochloride plus Docetaxel

Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

The Affiliated Hospital of Qingdao University

OTHER